treatment results after 11 days
    swiss medica in news

Stem cell transplantation has the ability to cut new brain lesions in multiple sclerosis

New studies have proven that stem cell transplantation is much more effective than mitoxantrone for multiple sclerosis patients and their brain lesion. Italian researchers show that after undergoing stem cell treatments, patients had a lot less brain lesions than those on mitoxantrone. The reduction of new T2 lesion was astonishing 79%.

Giovanni Mancardi and his team from the University of Genova in Italy worked on this study for 4 years, whilst receiving support from the Italian Multiple Sclerosis Foundation. The focus was not on the later benefits of the stem cell treatment, but they found it evident that alongside fewer brain lesions, patients have less relapses annually, as well. The team believes that this treatment could easily be a lot more superior compared to the current treatments that are widely used for dealing with multiple sclerosis. It is also an option for all the patients who don’t respond to other treatments, said the team.

21 patients from seven Italian and Spanish centers participated in this research. Their average age was 35 and all of them had either relapsing-remitting or secondary progressive multiple sclerosis. They were randomized to intensive immunosuppression followed by either mitoxantrone or autologous hematopoietic stem cell transplantation every month for 6 months.

Median of T2 lesions were 2.5 versus 8, when comparing stem cell treatment with mitoxantrone, making stem cell treatment significantly more successful. Relapses also decreased more with stem cell treatment than it did with mitoxantrone.

This research is still not finished, and the team will proceed to phase III trial. They hope that their work helps the stem cell therapy become widely licensed worldwide.

Advanced medical equipment at Swiss Medica Clinic


What they say about us

All form fields are required.